Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GW Pharmaceuticals Plc's Sativex receives regulatory approval in Switzerland


Wednesday, 27 Nov 2013 02:00am EST 

GW Pharmaceuticals Plc:Says it has received regulatory approval for its prescription medicine Sativex in Switzerland.Says a full marketing authorization has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications.Says launch timing is dependent on completion of pricing and reimbursement procedures.Says Sativex will be commercialized in Switzerland by GW's European partner, Almirall SA.Says Sativex is now approved in a total of 23 countries. 

Company Quote

417.75
3.75 +0.91%
11:17am EST